Business Wire

VA-NEUSTAR

4.10.2017 06:04:41 CEST | Business Wire | Press release

Share
Neustar and NetFoundry Deliver World’s First Identity-Secured IoT Networking Solution

Neustar , Inc., a trusted, neutral provider of real-time information services, and NetFoundry™, a Tata Communications business incubated in Tata Communications’ ‘Shape the Future’ program, announced an integration between the Neustar Trusted Device Identity (TDI) solution and NetFoundry’s Application Specific Networking (ASN) platform , which provides customers with superior security, extending trusted identity based solutions across multiple networks and clouds.

The Neustar Trusted Device Identity (TDI) solution, built-on-top of the NetFoundry Application-Specific platform, reduces the time, cost and risk of implementing secure end-to-end solutions.

"Creating a secure end-to-end environment based on identity for devices and secure core transport to the edge is necessary for IoT to gain adoption," said Hank Skorny, SVP of IoT, Neustar. “Neustar and NetFoundry together provide a highly secure, highly manageable and recoverable environment to secure communications between any and all parties.”

“Traditional networking with the use of PKI and firewalls has been manageable to date, but the digitally transformed applications landscape requires the app contexts, such as identity, to programmatically define the network,” said Galeal Zino, Founder of NetFoundry. “Our platform enables leading solutions from innovative partners such as Neustar to program the network to enforce each application’s identity, access and security policies, rather than trying to manually manage a separate set of policies on the network.”

PKI-based identity management solutions are leaving IoT enterprises exposed and overburdened with the need for certificate management of thousands of devices. Neustar TDI delivers a next-generation approach to trusted identity management, offering the scale and security required for the Internet of Things. By applying this new approach to traditional PKI with multi-factor device authentication, Neustar TDI can authenticate and revoke identities in real-time, monitor and detect behavior anomalies, as well as enable organizations to quickly isolate and recover from breaches. This way the IT Network Operations Center (NOC) can take back control of revocation and restoration.

The NetFoundry platform enables leading solution providers like Neustar to integrate application specific networking into their solutions (“AppWANs”) with no restrictions on network providers, VPNs or custom CPE. Each AppWAN is driven by the context of the application, such as identity, compliance and performance needs, enforcing application level micro-segmentation across any set of networks and clouds, with superior performance and security results, while enabling complete, centralized control and visibility of each AppWAN.

The Neustar and NetFoundry implementation is ideal for microservices-based architectures, such as the one developed by the open source EdgeX Foundry project of the Linux Foundation, of which both Neustar and NetFoundry are founding members.

Customers using a TDI and NetFoundry end-to-end solution benefit from:

  • Real-time activation and revocation
  • Route validation
  • Secure remote management
  • Anomaly detection
  • Multi-factor authentication
  • Recovery without the need to re-key
  • Endpoint and identity management
  • The security and efficiency of end-to-end identity driven networking
  • Enhanced application performance with dynamic path optimization and remediation
  • Application level micro-segmentation with data-in-motion encryption and isolation

A secure end-to-end Networking Platform as a Service (NPaaS) solution will be demonstrated by Neustar and NetFoundry at the Linux Foundation/EdgeX Foundry booth at IoT Solutions World Congress in Barcelona, Spain from October 3-5.

For more information about Neustar TDI and EdgeX Foundry, read our blog .

About NetFoundry

NetFoundry is leading the next generation of networking providers, using software to connect application endpoints, as opposed to traditional SD-WAN and MPLS WANs which use CPE to connect sites. Each NetFoundry AppWAN is driven by the contexts of the app, and can be software integrated into partner services and platforms. Security and performance are built into each AppWAN, so that customers can choose any set of networks and clouds and still get the security, compliance and reliability they require. NetFoundry is a Tata Communications business incubated in Tata Communications’ Shape the Future program, headquartered in Charlotte, North Carolina, with offices in San Francisco, Austin, New York, Bangalore and Singapore.

About Neustar

Every day, the world generates roughly 2.5 quadrillion bits of data. Neustar isolates certain elements and analyzes, simplifies and edits them to make precise and valuable decisions that drive results. As one of the few companies capable of knowing with certainty who is on the other end of every interaction, we’re trusted by the world’s great brands to make critical decisions some 20 billion times a day. We help marketers send timely and relevant messages to the right people. Because we can authoritatively tell a client exactly who is calling or connecting with them, we make critical real-time responses possible. And the same comprehensive information that enables our clients to direct and manage orders also stops attackers. We know when someone isn’t who they claim to be, which helps stop fraud and denial of service before they’re a problem. Because we’re also an experienced manager of some of the world’s most complex databases, we help clients control their online identity, registering and protecting their domain name, and routing traffic to the correct network address. By linking the most essential information with the people who depend on it, we provide more than 11,000 clients worldwide with decisions—not just data. More information is available at https://www.neustar.biz .

Contact:

Neustar Media
Kim Maynard, 415-238-0362
Kimberly.Maynard@neustar.biz
or
Netfoundry Media
Orietta Sutherberry, +44-780313-7126
osutherberry@zonicgroup.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye